Dr. Ravi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 2004 - 2007
Quinnipiac University Frank H. Netter MD School of Medicine/St Vincent's Medical CenterResidency, Internal Medicine, 2001 - 2004
University of Kerala Medical CollegeClass of 1999
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2007 - Present
GA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
AL State Medical License 2023 - 2025
AZ State Medical License 2023 - 2025
LA State Medical License 2023 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Start of enrollment: 2010 Sep 01
- Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma Start of enrollment: 2011 Nov 03
- Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study Start of enrollment: 2013 Mar 29
- Join now to see all
Publications & Presentations
PubMed
- Clinical Variables Influencing Outcomes in Patients with Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas): Single-Institution Study of...Alicia Gingrich, Sintawat Wangsiricharoen, Madeline B Torres, Vinod Ravi, Ravin Ratan
Annals of Surgical Oncology. 2024-11-01 - MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients.Xiaohui Niu, Vinod Ravi, Boyao Shan, Qiuxiang Guo, Haosong Shi
Future Oncology. 2024-09-17 - Does the Primary Tumor Site Drive Biology for Patients With Synovial Sarcoma?Riddhi R Patel, George L Delclos, Stacia M DeSantis, Michael B Cannell, Philip J Lupo
American Journal of Clinical Oncology. 2024-09-03
Lectures
- Artificial Intelligence (AI) and machine learning (ML) in risk prediction of hospital acquired pressure injuries (HAPIs) among oncology inpatients.2019 ASCO Annual Meeting - 6/1/2019
- TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Genomic subtypes of angiosarcoma: A comprehensive genomic profiling (CGP) study.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapyRavi V, Raut CP, Patel SR, DeLaney TF
http://www.uptodate.com/contents/desmoid-tumors-epidemiology-risk-factors-molecular-pathogenesis-cli
UpToDate, Wolters Kluwer Health - 2012-10-26 - Desmoid tumors: Systemic therapyRavi V, Patel SR
http://www.uptodate.com/contents/desmoid-tumors-systemic-therapy
UpToDate, Wolters Kluwer Health - 2012-03-22
Press Mentions
A Pilot Study of Oraxol in Subjects with Cutaneous AngiosarcomaJune 4th, 2018
Oncology Hashtag Project Leads to a Sarcoma Hashtag with Rallying Cry for More Treatment OptionsJuly 22nd, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
